Management of Neuropathic Pain

Eisenberg, Elon

doi:10.17925/enr.2006.00.02.20

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In reviews of unlicensed drugs and neuropathic pain more generally, the lack of standardisation of outcome measures across trials has required a looser definition of response rate. Previous reviews [ 19 - 21 ] have reported NNTs based on the criterion of 50% pain reduction, but NNTs have also been derived from various pain scales or approximations made where data were not available. For consistency, we have reported similarly-derived NNT (and NNH) values for the placebo comparisons.…”

Section: Discussionmentioning

confidence: 99%

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Quilici

Chancellor

Löthgren³

et al. 2009

BMC Neurol

196

143

View full text Add to dashboard Cite

Background: Few direct head-to-head comparisons have been conducted between drugs for the treatment of diabetic peripheral neuropathic pain (DPNP). Approved or recommended drugs in this indication include duloxetine (DLX), pregabalin (PGB), gabapentin (GBP) and amitriptyline (AMT). We conducted an indirect meta-analysis to compare the efficacy and tolerability of DLX with PGB and GBP in DPNP, using placebo as a common comparator.

show abstract

Section: Discussionmentioning

confidence: 99%